Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate Patent Expiration
Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate is Used for treating HIV-1 infection in various patient populations, including those with no prior treatment history or virologically suppressed individuals. It was first introduced by Janssen Products Lp
Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Symtuza | US10786518 | Compositions and methods of treating HIV | Jul 19, 2038 | Janssen Prods |
Symtuza | US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Oct 06, 2032 | Janssen Prods |
Symtuza | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Janssen Prods |
Symtuza | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Janssen Prods |
Symtuza | US8148374 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Janssen Prods |
Symtuza | US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor | Dec 26, 2026 | Janssen Prods |
Symtuza | US7390791 | Prodrugs of phosphonate nucleotide analogues | Apr 17, 2025 | Janssen Prods |
Symtuza | US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb 16, 2024
(Expired) | Janssen Prods |
Symtuza | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Janssen Prods |
Symtuza | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Janssen Prods |
Symtuza | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Janssen Prods |
Symtuza | US7470506 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
Symtuza | US8597876 | Method of treating HIV infection |
Jun 23, 2019
(Expired) | Janssen Prods |
Symtuza | US9889115 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate's patents.
Latest Legal Activities on Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Recordation of Patent Grant Mailed Critical | 29 Sep, 2020 | US10786518 |
Patent Issue Date Used in PTA Calculation Critical | 29 Sep, 2020 | US10786518 |
Email Notification Critical | 15 Sep, 2020 | US10786518 |
Issue Notification Mailed Critical | 09 Sep, 2020 | US10786518 |
Application Is Considered Ready for Issue Critical | 24 Aug, 2020 | US10786518 |
Dispatch to FDC | 24 Aug, 2020 | US10786518 |
Issue Fee Payment Received Critical | 20 Aug, 2020 | US10786518 |
Issue Fee Payment Verified Critical | 20 Aug, 2020 | US10786518 |
Mailing Corrected Notice of Allowability | 16 Jul, 2020 | US10786518 |
Printer Rush- No mailing | 16 Jul, 2020 | US10786518 |
Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate's Family Patents
